Zymeworks Inc. (NASDAQ:ZYME)
| Market Cap | 1.90B+52.4% |
| Revenue (ttm) | 37.13M-69.8% |
| Net Income | -149.99M-103.6% |
| EPS | -2.02-108.2% |
| Shares Out | 73.57M |
| PE Ratio | n/a |
| Forward PE | 25.15 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 486,980 |
| Open | 25.28 |
| Previous Close | 25.26 |
| Day's Range | 25.28 - 26.35 |
| 52-Week Range | 16.00 - 31.34 |
| Beta | 1.17 |
| Analysts | Buy |
| Price Target | 41.40(+60.53%) |
| Earnings Date | Nov 5, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About ZYME
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ZYME stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ZYME holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ZYME's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ZYME Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ZYME patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ZYME from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ZYME
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $44.37M |
| IWMiShares Russell 2000 ETF | $30.46M |
| IBBiShares Biotechnology ETF | $13.50M |
| IWOiShares Russell 2000 Growth ETF | $10.62M |
| DFASDimensional - US Small Cap ETF | $7.97M |
| VTWOVanguard Russell 2000 ETF | $7.96M |
Estimated from each fund’s disclosed top holdings × AUM
ZYME Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ZYME’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score